Form 4: Q32 Bio CSO Granted 37,500 RSUs in Equity Compensation

Q32 Bio's Chief Scientific Officer, Shelia M. Violette, was granted 37,500 restricted stock units, vesting over a three-year period.

Summary

• Shelia M. Violette, Chief Scientific Officer of Q32 Bio Inc. (QTTB), acquired 37,500 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for the RSU grant was February 24, 2026.
• The RSUs vest in four equal installments: 25% at 6 months, 25% at 12 months, 25% at 24 months, and 25% at 36 months from the grant date.
• Each RSU represents a contingent right to receive one share of Q32 Bio common stock.
• Following this transaction, Shelia M. Violette directly beneficially owns 93,069 shares of common stock.
• Additionally, 36,277 shares are indirectly beneficially owned by Violette Holdings LLC, where the reporting person is a manager.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it represents a routine executive compensation event that aligns the Chief Scientific Officer's interests with long-term shareholder value through equity.

Positives

• The grant of Restricted Stock Units aligns the Chief Scientific Officer's long-term interests with those of shareholders, incentivizing sustained company performance.
• Equity compensation is a standard practice to attract and retain key executive talent.

Negatives

• The vesting schedule means the full benefit of the grant is not immediate and is contingent on continued employment.
• The future issuance of shares upon vesting will result in a minor dilution for existing shareholders.

Risks

• The value of the RSUs is subject to the future market price fluctuations of Q32 Bio Inc. common stock.
• Unvested RSUs may be forfeited if the reporting person's employment with Q32 Bio Inc. terminates before the vesting dates.
• The indirect beneficial ownership through Violette Holdings LLC introduces a layer of complexity, though the reporting person disclaims beneficial ownership beyond her pecuniary interest.

Future Outlook

The RSU grant signifies a continued commitment from the Chief Scientific Officer to Q32 Bio's long-term success, with the vesting schedule providing an incentive for sustained performance over the next three years.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units is a common and widely accepted form of long-term incentive compensation for executives in the biotechnology and pharmaceutical industries. This practice aims to align the interests of key management with those of shareholders by tying a significant portion of their compensation to the company's stock performance and longevity.

Comparison to Industry Standards

• RSU grants are a standard component of executive compensation packages across the biotech sector, similar to practices at companies like Moderna, BioNTech, and Regeneron, which use equity to incentivize innovation and long-term value creation.
• The multi-year vesting schedule is typical for such grants, ensuring executive retention and commitment over strategic development cycles, comparable to vesting schedules seen in similar-stage biopharmaceutical companies.

Related Party Transactions

• Shelia M. Violette indirectly beneficially owns 36,277 shares through Violette Holdings LLC, where she is a manager. She disclaims beneficial ownership of these shares except to the extent of her pecuniary interest.

Stakeholder Impact

• Shareholders: The RSU grant is intended to align executive incentives with shareholder value creation, potentially leading to better long-term performance. However, it also implies future minor dilution upon vesting.
• Employees: The grant reinforces the company's commitment to retaining key talent, which can positively impact employee morale and stability.
• Management: The Chief Scientific Officer receives a significant equity stake, incentivizing her to contribute to the company's growth and success over the vesting period.

Next Steps

• The RSUs will vest in four equal installments over the next three years, contingent on continued employment.
• Upon vesting, the reporting person will receive shares of Q32 Bio common stock.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to an executive, which is a standard compensation practice and does not provide new fundamental information that would warrant a change in investment recommendation. The transaction is expected and primarily serves to align management incentives.

Keywords

Q32 Bio, QTTB, Restricted Stock Units, RSU, Equity Grant, Insider Transaction, Executive Compensation, Beneficial Ownership, Chief Scientific Officer